Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2023-04-10 Director's Dealing
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory disclosure for insider share transactions or changes in ownership status by company executives. In the provided taxonomy, 'Director's Dealing' (DIRS) is the correct category for reports detailing share transactions or ownership changes by company directors and executives.
2023-04-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by executives to disclose their personal shareholdings and changes therein. This corresponds to the 'Director's Dealing' category, which covers insider trades and ownership reports by company directors and executives.
2023-04-10 Korean
타인에대한채무보증결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from JW Pharmaceutical regarding a 'Decision on Debt Guarantee for Others' (타인에 대한 채무보증 결정). It details a financial guarantee provided by the company for a subsidiary, including the amount, duration, and board approval details. This type of disclosure is a standard regulatory requirement for material corporate events in South Korea (DART system). Since it does not fit into specific categories like M&A, dividends, or earnings, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2023-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a General Meeting of Shareholders (AGM). It details the approval of financial statements, dividend declarations, and the election of board members and audit committee members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it provides the outcome of the shareholder votes held on 2023-03-29.
2023-03-29 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of outside directors. This type of corporate governance disclosure specifically pertains to changes in the board of directors, which falls under the 'Board/Management Information' category.
2023-03-29 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the 67th fiscal year (2022), which is the standard Korean regulatory filing equivalent to an Annual Report (10-K). It contains comprehensive company information, financial data, management discussion, and governance details for the full fiscal year ending December 31, 2022. FY 2022
2023-03-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.